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Abstract
Background: Initiation and titration of human regular U-500 insulin (U-500R) with a dosing algorithm of either thrice
daily (TID) or twice daily (BID) improved glycemic control with fewer injections in patients with type 2 diabetes treated
with high-dose, high-volume U-100 insulin. The objective of this analysis was to compare patient-reported outcomes
between U-500R TID and BID treatment groups in this titration-to-target randomized, clinical trial.
Methods: In this 24-week, open-label, parallel trial, 325 patients were randomized to TID (n = 162) or BID (n = 163) U-500R
after a 4-week lead-in period (screening). The Treatment Related Impact Measure-Diabetes (TRIM-D) and EQ-5D-5L
questionnaires were administered at screening, baseline/randomization, and endpoint (24 weeks). The Visual Analog
Scale-Injection Site Pain (VAS-ISP) was assessed at baseline/randomization, 12 weeks, and endpoint.
Results: The TRIM-D showed statistically significant improvements in overall scores from baseline to endpoint for both
BID and TID groups, most domains in the TID group, and all domains in the BID group. The BID group achieved better
scores than the TID patients in overall and in treatment burden, daily life, and compliance domains (p < .05). EQ-5D-5L
index scores showed no statistically significant differences for TID and BID groups (and no differences between TID and
BID groups) from baseline to endpoint. VAS-ISP scores improved for both treatment groups (−5.60 TID; −6.47 BID; p < .05
for both) from baseline to endpoint.
Conclusions: U500 can be successfully titrated for improved glycemic control using BID and TID regimens with
diabetes-specific Patient-Reported Outcomes showing improvements in both arms; however, BID had better scores
than TID in overall, treatment burden, daily life, and compliance domains.
Trial registration: These secondary analyses are based on the study first received January 22, 2013 and reported in
Clinical Trial Registry No.: NCT01774968.
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Background
Severely insulin-resistant patients (daily insulin require-
ment >200 units or >2 units/kg [1, 2]) with type 2 diabetes
treated with high-dose insulin regimens are particularly
burdened by longstanding inadequate glycemic control,
multiple daily insulin injections, frequent glucose moni-
toring, obesity, highly prevalent comorbidities, and high
healthcare costs, and often have compromised adherence
[1–3]. Treatment using high doses of U-100 insulins in-
tensifies barriers to use, as the number of daily injections,
injection site discomfort, costs, and impaired adherence
also increase [4–7].
Highly concentrated human regular U-500 insulin
(U-500R; Humulin® R U-500, Eli Lilly and Company)
is a treatment option that may alleviate some of these
barriers. For a patient transitioning from a high-dose,
high-volume regimen of U-100 insulin (100 units/mL)
to one using U-500R, there is a reduction in the vol-
ume and the number of daily injections [3], in
addition to the potential for decreased costs and im-
proved adherence [4, 7]. While the use of U-500R has
also been shown to improve patient satisfaction com-
pared to high-dose U-100 insulins [5, 6] in previous
retrospective analyses, this is the first study measur-
ing patient perceptions in a controlled, randomized,
clinical trial setting using U-500R.
In the clinical trial, 325 severely insulin-resistant pa-
tients with type 2 diabetes on high-dose U-100 insulin
(>200 units of insulin/day) with or without oral antihy-
perglycemic agents were randomized to receive U-500R
thrice daily (TID) or twice daily (BID), which was initi-
ated and titrated over a 24-week period in place of U-100
insulins [3]. The objective of this analysis within the
primary study was to compare patient-reported outcomes
in the form of a diabetes treatment-specific questionnaire
(Treatment Related Impact Measure-Diabetes [TRIM-D]),
a quality of life questionnaire (EQ-5D-5L), and a pain
scale, the Visual Analog Scale-Injection Site Pain (VAS-
ISP), before and after initiation of U-500R in TID and BID
treatment groups. The hypothesis was that all instruments
would improve with treatment on concentrated U-500R
given the expected reduction in number of daily injections




The detailed trial design, including a description of the
study population, has been previously reported but is dis-
cussed here briefly [3]. Baseline demographic and clinical
characteristics of the TID and BID patients are provided in
Table 1. For the overall study population, baseline body
mass index was 41.9 ± 7.5 kg/m2, HbA1c was 8.7 % ± 1.0 %,
median number of daily injections was 5 (range 2–10), and
total daily dose (TDD) was 287.5 ± 80.5 units/day (2.4 ± 0.8
units/kg/day) [3]. Baseline insulin therapies included basal
bolus (69.6 % [96.5 % analog insulins]), premixed insulin
(12.3 %), basal only (6.2 %), and other (12.0 %) [3]. All pa-
tients were prior U-100 insulin users who were placed on a
4-week lead-in period, during which U-100 doses were veri-
fied and adjusted per investigators’ judgment. Patients were
then randomized to receive subcutaneous U-500R TID
(n = 162) or BID (n = 163) [3]. The syringes provided for ad-
ministration were 6-mm, 31-gauge U-100 insulin syringes
(Becton, Dickinson and Company) and dosing was recom-
mended 30 min before meals for both treatment groups.
Patient-reported outcome measures, including the TRIM-D
[8], EQ-5D-5L [9, 10], and VAS-ISP [11], were used to
compare changes in diabetes treatment-related impact
measures, quality of life, and injection site pain from base-
line to endpoint between and within the BID and TID
treatment groups. The TRIM-D and EQ-5D-5L assess-
ments were performed at visit 1 (screening, -4 weeks), visit
3 (baseline/randomization, 0 weeks), and visit 16 (endpoint,
24 weeks) or early termination (if patients did not reach
24 weeks of study). The VAS-ISP was completed at visit 3
(baseline/randomization), visit 12 (12 weeks), and visit 16
(endpoint). Descriptive statistics by treatment and injection
method were also provided as part of this analysis. The eth-
ics review boards provided written approval of the study
Table 1 Baseline demographics and clinical characteristics of






Male, n (%) 83 (51.2) 89 (54.6) .54
Race, n (%) .66b
White 133 (82.1) 133 (81.6)
Black 21 (13.0) 19 (11.7)
Asian 2 (1.2) 4 (2.5)
Native American 3 (1.9) 1 (0.6)
Other 3 (1.9) 6 (3.7)
Ethnicity (Hispanic), n (%) 32 (19.8) 30 (18.4) .76
Age, yearsc 55.3 ± 10.5 55.5 ± 9.0 .86
Weight, kg 120.9 ± 25.1 122.9 ± 26.2 .48
BMI, kg/m2 41.8 ± 7.6 41.9 ± 7.3 .95
Baseline HbA1c 8.7 ± 1.1 8.7 ± 1.0 .87
Diabetes duration, years 14.9 ± 6.8 15.5 ± 8.0 .51
TDD, (U-100, final), units 287.1 ± 79.9 287.8 ± 81.2 .94
Number of injections, median
[min, max]
5 [2, 9] 5 [2, 10] .96
Abbreviations: BID twice daily; BMI body mass index; HbA1c glycated
hemoglobin; TDD total daily dose; TID thrice daily
p values for continuous variables are based on analysis of variance, and for
categorical variables, Fisher’s exact or chi-square test
aExcerpted from reference [3] Hood RC, et al. 2015
bCombined values
cValues are presented as means ± SD unless otherwise noted
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protocol and the informed consent form. The study was
conducted in accordance with the International Conference
on Harmonisation Guidelines for Good Clinical Practice
and the Declaration of Helsinki and all patients provided
written informed consent.
Measures
The TRIM-D is a validated, patient-reported out-
come measure that assesses treatment-related impact
on participants with type 1 or type 2 diabetes [8, 12,
13]. The instrument consists of 28 items that are
measured on a 5-point Likert scale, with higher
scores indicating a better health state. TRIM-D items
make up the following five domains: treatment bur-
den (six items), daily life (five items), diabetes man-
agement (five items), compliance (four items), and
psychological health (eight items). For example,
items on the compliance domain depict how often a
medication is missed, delayed, or postponed on a re-
sponse scale ranging from never/almost never to al-
most always/always. Transformed scale scores range
from 0 to 100, with higher scores indicating a better
health state (less negative impact). The reliability
and validity for TRIM-D has been previously
assessed [12].
The EQ-5D-5L is a generic, well-validated, patient-
reported outcome measure consisting of the descriptive
system and Visual Analog Scale (EQ-5D VAS) [9, 10].
The descriptive system captures 5 dimensions (mobility,
self-care, usual activity, pain/discomfort, and anxiety/de-
pression), and each dimension has 5 levels (no problems,
slight problems, moderate problems, severe problems,
and extreme problems). The respondents were asked to
indicate their health status by checking item boxes on
the questionnaire that fit the way they felt about their
health on that day. The EQ-5D VAS measures the re-
spondent’s self-rated health on a 20-cm vertical VAS
numbered from 0 to 100, with 0 representing the worst
health and 100 the best health imaginable. The EQ-5D-
5L has been validated in a diverse patient population in
6 countries and many different chronic disease states, in-
cluding diabetes, for all dimensions and all levels [10].
Reliability and responsiveness remain to be assessed for
the EQ-5D-5L [10].
The VAS-ISP assesses injection site pain over the past
24 h using a 100-mm horizontal VAS with anchors from
“no pain” to “as severe as I can imagine” derived from
Huskisson [11]. Early in the study, the VAS-ISP version
of the questionnaire administered in this trial was modi-
fied from pain intensity ‘now’ to a corrected version of
the VAS-ISP questionnaire with the time frame of the
‘past 24 h’. Results from both instruments were analyzed
and found to be comparable. The reliability and respon-
siveness of the VAS-ISP has not been assessed.
Statistical analyses
Baseline measurements for continuous variables were
evaluated using analysis of variance. The EQ-5D-5L US
Index and EQ-5D VAS values were calculated using the
crosswalk method [10]. The TRIM-D, EQ-5D-5L, and
VAS-ISP scores were compared between treatment
groups at screening and baseline using analysis of co-
variance (ANCOVA). Change from baseline to endpoint
scores were compared between treatment groups using
the ANCOVA model with treatment as factor, baseline
HbA1c, baseline TDD, investigator site, and baseline
score as covariates. Comparisons of within-treatment
group scores were conducted using mixed-effect model
repeated measures (MMRM) with treatment, visit, inter-
action between treatment and visit, baseline HbA1c,
TDD, investigator site, and baseline score as covariates
using an unstructured covariance matrix.
The study population was categorized based on reduc-
tion of per-day insulin injections in the transition from
U-100 to U-500 (0–2, 3–4, >4 per day). TRIM-D and
EQ-5D-5L scores for subgroups were compared between
treatment groups using an ANCOVA model. Based on
the conventional definition of 80 % compliance being
clinically meaningful for adherence to diabetes medica-
tions, an arbitrary cutoff of TRIM-D compliance score
≥80 (the lowest and highest possible raw scores are 28
and 140, and after transformation, the lowest and high-
est possible score is 0–100) was used to compare the
percentage achieving scores of ≥80 versus <80 between
the two treatment groups [14, 15]. Logistic regression
was used with treatment, baseline score, and baseline
stratification variables (baseline HbA1c ≤8 % or >8 %,
baseline TDD ≤300 or >300 units) as independent vari-
ables. The dependent variable was patients achieving a
TRIM-D score ≥80.
The sample size calculation was based on the primary
outcome: change in HbA1c from randomization to week
24 [3]. It was estimated that 260 completers would pro-
vide at least 80 % probability to determine non-
inferiority of BID to TID, or vice versa, for the primary
endpoint (non-inferiority margin 0.4 %). Patient-
reported outcomes were exploratory. The p-values < .05
were considered statistically significant. All analyses
were performed using SAS version 9.2 or higher (SAS
Institute, Inc., Cary, NC) and were based on the full ana-
lysis set.
Results
Baseline demographic and clinical characteristics of pa-
tients titrated to the TID and BID algorithms were well
balanced (Table 1). The two treatment groups were
comparable at baseline with no significant differences in
these measured variables.
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Table 2 Comparisons of TID and BID dosing algorithms using TRIM-D patient-reported outcomes
TRIM-D Domain U-500R Treatment (n) Mean Actual Value (SD) Change from Baseline (MMRM)
LSM (95 % CI)a
LSM Difference between
Treatments (95 % CI) vs. U-500R TIDb
Overall
Screening TID (161) 60.28 (13.61) −2.65 (−4.77,−0.53)* 0.50 (−2.57, 3.56)
BID (159) 60.77 (14.27) −2.53 (−4.67,−0.38)*
Baseline TID (161) 61.35 (14.59) 1.09 (−2.05, 4.22)
BID (161) 62.44 (14.00)
Endpoint TID (159) 68.31 (14.14) 6.04 (3.81, 8.26)** 3.52 (0.93, 6.11)*
BID (153) 72.44 (12.57) 10.06 (7.82, 12.30)**
Treatment burden
Screening TID (160) 60.37 (18.40) −2.75 (−6.12, 0.63) −1.23 (−5.57, 3.11)
BID (159) 59.15 (20.91) −2.63 (−6.01, 0.75)
Baseline TID (160) 62.69 (19.39) − −2.48 (−6.93, 1.97)
BID (160) 60.21 (21.02)
Endpoint TID (158) 68.91 (19.31) 6.23 (2.70, 9.75)* 5.03 (0.99, 9.06)*
BID (153) 72.97 (19.84) 12.24 (8.71, 15.77)**
Daily life
Screening TID (161) 63.72 (17.38) −0.72 (−3.77, 2.32) −0.50 (−4.52, 3.52)
BID (158) 63.22 (19.10) −1.46 (−4.53, 1.62)
Baseline TID (161) 62.50 (17.69) − 0.97 (−2.95, 4.89)
BID (161) 63.47 (18.07)
Endpoint TID (159) 66.17 (17.78) 1.75 (−1.44, 4.93) 4.01 (0.41, 7.62)*
BID (153) 70.63 (17.57) 6.58 (3.37, 9.79)**
Diabetes management
Screening TID (161) 40.18 (19.53) −3.71 (−7.07,−0.35)* 4.27 (−0.15, 8.69)
BID (158) 44.45 (20.62) 0.13 (−3.26, 3.52)
Baseline TID (161) 43.15 (20.83) − 0.91 (−3.67, 5.49)
BID (161) 44.07 (20.95)
Endpoint TID (159) 57.02 (18.92) 13.40 (9.89, 16.92)** 0.52 (−3.62, 4.65)
BID (153) 57.87 (19.75) 14.89 (11.35, 18.43)**
Compliance
Screening TID (161) 65.06 (17.34) −3.04 (−5.79,−0.29)* 1.24 (−2.64, 5.11)
BID (158) 66.30 (17.84) −2.58 (−5.37, 0.22)
Baseline TID (161) 67.43 (17.09) − 2.02 (−1.76, 5.79)
BID (161) 69.45 (17.33)
Endpoint TID (159) 73.00 (16.87) 5.31 (2.43, 8.19)** 4.48 (1.50, 7.47)*
BID (153) 78.12 (14.52) 9.89 (6.98, 12.80)**
Psychological health
Screening TID (161) 68.09 (19.17) −2.90 (−5.67,−0.13)* −0.14 (−4.36, 4.08)
BID (159) 67.95 (19.20) −5.00 (−7.80,−2.20)**
Baseline TID (161) 68.02 (19.07) − 3.49 (−0.50, 7.47)
BID (161) 71.51 (17.23)
Endpoint TID (159) 73.90 (19.86) 4.57 (1.66, 7.47)* 3.22 (−0.11, 6.56)
BID (153) 79.49 (16.00) 7.50 (4.58, 10.43)**
Abbreviations: BID twice daily; CI confidence interval; LSM least-square mean; MMRM mixed model for repeated measures; SD standard deviation; TID thrice daily;
TRIM-D Treatment Related Impact Measure-Diabetes; U-500R human regular U-500 insulin
ap-values and 95 % CI of difference of LSM of change from baseline were from the MMRM model
bp-values and 95 % CI of difference of LSM of change from baseline were from the ANCOVA model
*p < .05; **p < .001
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TRIM-D
Patients within each treatment group had statistically
significant improvement overall and within each TRIM-
D domain (treatment burden, daily life [BID only], dia-
betes management, compliance, and psychological
health) from baseline to endpoint (Table 2). Individuals
in the BID group achieved statistically significant im-
proved scores overall, and in the treatment burden, daily
life, and compliance domains when compared to those
in the TID group at endpoint.
The median number of U-100 injections per day at
baseline was five for both groups, with a range of 2 to 9
Table 3 Relationship between TRIM-D overall and domain scores and the number of reduced injections from baseline to endpoint








LSM Change from Baseline
(SE)
Overall 0–2 TID (121) 67.78 (14.60) 5.74 (13.98) 6.15 (1.08)*
BID (58) 72.73 (12.56) 7.95 (13.37) 10.51 (1.60)*
3–4 TID (36) 70.54 (12.39) 11.32 (15.78) 8.48 (2.02)*
BID (85) 72.06 (12.89) 10.83 (13.71) 9.86 (1.29)*
>4 TID (2) 59.82 (16.41) 3.57 (6.31) −1.22 (8.31)
BID (10) 74.02 (10.65) 10.27 (10.88) 9.89 (3.79)*
Treatment burden 0–2 TID (120) 68.65 (19.77) 5.36 (21.62) 7.09 (1.69)*
BID (58) 70.62 (21.93) 9.55 (25.43) 10.84 (2.47)*
3–4 TID (36) 70.37 (18.06) 8.91 (21.92) 6.61 (3.14)*
BID (85) 74.59 (18.91) 15.08 (21.02) 12.78 (2.00)*
>4 TID (2) 58.33 (17.68) 0.00 (11.79) −3.42 (12.90)
BID (10) 72.92 (14.33) 9.58 (19.35) 10.17 (5.89)
Daily life 0–2 TID (121) 65.51 (18.76) 2.24 (19.05) 2.61 (1.50)
BID (58) 72.52 (17.34) 7.61 (19.99) 8.85 (2.22)*
3–4 TID (36) 68.89 (14.40) 9.17 (17.42) 6.75 (2.81)*
BID (85) 69.24 (17.33) 7.18 (19.02) 6.68 (1.79)*
>4 TID (2) 57.50 (3.54) −7.50 (10.61) −8.59 (11.54)
BID (10) 71.50 (21.61) 4.00 (16.12) 5.46 (5.27)
Diabetes
management
0–2 TID (121) 56.46 (19.32) 12.33 (23.57) 12.95 (1.72)*
BID (58) 57.74 (20.00) 9.63 (24.48) 14.09 (2.55)*
3–4 TID (36) 59.44 (17.92) 19.83 (27.95) 15.08 (3.23)*
BID (85) 58.18 (20.15) 15.29 (25.55) 13.87 (2.06)*
>4 TID (2) 47.50 (10.61) 12.50 (17.68) 5.38 (13.29)
BID (10) 56.00 (16.30) 15.00 (16.83) 12.38 (6.06)*
Compliance 0–2 TID (121) 72.47 (17.61) 4.17 (15.47) 4.27 (1.24)*
BID (58) 77.51 (15.30) 8.76 (14.30) 9.77 (1.84)*
3–4 TID (36) 75.00 (14.56) 9.72 (22.43) 7.34 (2.33)*
BID (85) 78.09 (14.26) 9.12 (14.96) 9.16 (1.48)*
>4 TID (2) 68.75 (8.84) 3.13 (13.26) 0.13 (9.58)
BID (10) 81.88 (12.66) 7.50 (13.44) 9.27 (4.37)*
Psychological health 0–2 TID (121) 73.30 (20.56) 4.76 (17.85) 4.45 (1.38)*
BID (58) 81.51 (15.17) 5.60 (13.69) 9.39 (2.06)*
3–4 TID (36) 76.39 (17.12) 9.98 (15.79) 7.53 (2.59)*
BID (85) 77.61 (16.86) 8.01 (18.10) 7.28 (1.65)*
>4 TID (2) 65.63 (30.94) 7.81 (2.21) 0.78 (10.68)
BID (10) 83.75 (11.39) 13.13 (13.24) 11.32 (4.86)*
Abbreviations: BID twice daily; LSM least-square mean; SD standard deviation; SE standard error; TID thrice daily; TRIM-D Treatment Related Impact Measure-
Diabetes; U-500R human regular U-500 insulin
*p < .05; p-value and LSM of change from baseline were from an ANCOVA model
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for TID and 2 to 10 for BID (Table 1) [3]. Patients were
grouped by number of injections reduced from baseline
into three categories (0–2, 3–4, and >4), and these sub-
groups were analyzed separately for TRIM-D overall and
specific domains at endpoint (Table 3). Individuals in the
U-500R BID group reported significant improvements in
overall score and each domain when 0–2 and 3–4 injec-
tions were reduced from baseline. The individuals in the
TID group reported significant improvements in overall
and in each domain when 0–2 and 3–4 injections were
reduced from baseline (p < .05) except the daily life do-
main when 0–2 injections were reduced from baseline.
Significant differences may not have been seen in the >4
injections reduced category because of the small sample
size (two in the TID group and ten in the BID group).
The compliance domain scores in the BID treatment
group were significantly higher compared to the TID
treatment group (p = .03 in favor of BID vs. TID). The
proportion of patients achieving a TRIM-D compliance
score ≥80 was analyzed by subordinate analysis using lo-
gistic regression and 36 % (58/159) of patients in the TID
treatment group vs. 49 % (75/153) in the BID group had a
TRIM-D compliance score of ≥80 (odds ratio = 1.70; 95 %
confidence interval: 1.05–2.75; p = .03) (Table 4).
EQ-5D-5L
EQ-5D-5L index scores showed no statistically significant
differences between the TID and BID groups at screening,
baseline/randomization, and endpoint (Table 5). Visit
comparisons of total score for the overall population and
TID and BID groups were conducted separately. No sig-
nificant visit differences were found in scores between
screening and baseline or between baseline and endpoint.
Although the number of injections in the TID and
BID cohorts declined during the transition period of the
study [3], neither the treatment (TID or BID) nor the
number of reduced injections (i.e., 0–2, 3–4, or >4) had
significant effect on the EQ-5D-5L index scores.
Summaries of responses which best described the re-
spondent’s health on the five EQ-5D-5L domains (mobil-
ity, self-care, usual activities, pain/discomfort, anxiety/
depression) showed no statistically significant difference
between treatment groups at screening, baseline, or
endpoint.
Quantitative EQ-5D VAS scores for overall health at
screening, baseline, and endpoint in TID respondents were
70.0, 70.4, and 68.0, respectively (TID endpoint least-square
means p < .05 compared to baseline); whereas, scores in
BID respondents were not significantly different at 68.9,
70.8, and 70.0. Comparisons between TID and BID treat-
ment groups were not significantly different.
VAS-ISP
VAS-ISP demonstrated a significant improvement in in-
jection site pain from baseline to endpoint for TID and
BID treatment groups (least square means change from
baseline at visit 12, −7.36 TID; −5.85 BID; and at visit
16, −5.60 TID; −6.47 BID; p < .05; Fig. 1). No significant
difference of score reduction between BID and TID
groups was evident.
Discussion
This is the first analysis of prospective and comprehen-
sive patient-reported outcomes from a randomized, clin-
ical trial of severely insulin-resistant patients with type 2
diabetes who were switched from high-dose U-100 insu-
lin regimens to U-500R as insulin monotherapy. Consist-
ent with the initial study hypothesis, transitioning from
high-dose, high-volume U-100 insulin requiring multiple
daily injections and implementing TID or BID U-500R
dosing algorithms, most TRIM-D domain scores in pa-
tients demonstrated clinically relevant and significant
improvements from baseline to endpoint. By endpoint,
respondents in the BID group had experienced greater
perceived improvements in TRIM-D over time when
compared to the TID group. Respondents also reported
improved compliance from baseline for both groups,
and a higher proportion of BID group patients achieved
a TRIM-D compliance score ≥80.
As first reported by Hood et al. [3], the primary study
outcome, change in HbA1c between TID and BID, was
clinically equivalent between the two study groups
(−1.12 % TID;−1.22 % BID; difference,−0.10 %; 95 %
confidence interval:−0.33 to 0.12 %; noninferiority
margin, 0.4 %). Despite an increase in TDD and sig-
nificant reduction in HbA1c [3], both groups reported
an improvement in compliance scores. This could be
explained by better adherence with simplified insulin
regimens wherein up to 10 injections daily of U-100













95 % CI of
Odds Ratio
p-value
Number of patients with TRIM-D compliance score ≥80 58 (36.5) 75 (49.0) 133 (42.6) 1.70 1.05, 2.75 .03
Abbreviations: BID twice daily; CI confidence interval; n number of patients in a specified group; N total number of patients; TID thrice daily; TRIM-D Treatment
Related Impact Measure-Diabetes; U-500R human regular U-500 insulin
aCI and p-values were from a logistic regression model with fixed effects for treatment, baseline score and baseline stratification variables (Baseline A1C (≤8 %
or >8 %), Baseline TDD (≤300 or >300), and pooled investigator). p-value from this analysis was based on a null hypothesis that the odds ratio is one
Kabul et al. Health and Quality of Life Outcomes  (2016) 14:139 Page 6 of 9
were prescribed before randomization (often with
more than one insulin), compared to a monotherapy
regimen of two or three injections of U-500R post-
randomization.
Although EQ-5D VAS comparisons between the TID
and BID groups were not significantly different, individ-
uals in the TID group responded with statistically lower
health scores from baseline at endpoint. Because the
EQ-5D-5L is not diabetes specific, the assessment may
not have been sensitive enough to distinguish between
treatment groups.
Injection site pain was significantly reduced in both
treatment groups, which might be attributed to the re-
duced daily injection volume (−2.2 mL for TID and BID)
and reduced number of daily injections (−2 TID,−3 BID)
[3, 16]. This finding supports prior reports of reduced
injection site discomfort with use of concentrated U-500R
[5, 17–19].
Limitations of this study included the open-label de-
sign and lack of direct measures of compliance. Patient
perceptions of use while on vial and syringe versus pen
regimens prior to randomization to U-500R were not
evaluated separately, which could also have impacted pa-
tient perception of the new insulin regimen (vial and
syringe).
Since this analysis takes into account the patient perspec-
tive, an additional factor not analyzed here that could affect
the patient perception is the affordability of insulin. In re-
cent years, this has become a significant issue, especially for
those patients requiring high doses of insulin [20] to
achieve glycemic control. For the majority of patients in this
trial using basal + bolus analog insulin regimens (67 % of
patients) prior to randomization to U-500R, one would ex-
pect that the switch to U-500R would lead to a reduction in
daily insulin costs. This decrease might be expected to
occur after accounting for an increase in TDD from base-
line to endpoint regimens after 24 weeks as part of a
titration-to-target intensification. While this reduction in
real-world drug costs with transition to U-500R has
Table 5 EQ-5D-5L index score comparing 2 U-500R dosing al-















(95 % CI) vs.
U-500R TID







Baseline TID (162) – 0.00 (−0.03,
0.03)
BID (161) –







Abbreviations: BID twice daily; CI confidence interval; LSM least-square mean;
SE standard error; TID thrice daily; U-500R human regular U-500 insulin
ap-values and 95 % CI of difference of LSM of change from baseline were
from the MMRM model
** **
TID n = 51



























Fig. 1 Visual Analog Scale - Injection Site Pain evaluation from baseline to endpoint. Abbreviations: BID = twice daily; SD = standard deviation; TID = thrice
daily; VAS = visual analog scale. *Actual mean values of patients on U100 insulins ± SD are from corrected CRF data. **p-values are <0.05 for visit 12 and
visit 16 when least square mean change from baseline are calculated (−7.36 TID, -5.85 BID visit 12 and -5.60 TID, -6.47 BID visit 16)
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previously been reported as compared to propensity-
matched patients remaining on high-dose conventional
U-100 insulins [4, 7], further detailed economic analyses
on this topic would be of value to patients, payers, and
providers alike.
Conclusion
Our study findings indicate that initiation and titration of
U-500R leads to improved patient perception, improved
impact of diabetes treatment on functioning and well-
being, and less injection site discomfort following use of
high-dose, high-volume U-100 insulins in severely insulin-
resistant patients with type 2 diabetes. While both regimens
improved patient reported treatment-related diabetes mea-
sures, the twice-daily regimen showed more of an improve-
ment in certain patient reported domains when compared
to the thrice-daily regimen. Its impact on compliance, spe-
cifically, should therefore be considered when choosing an
appropriate U-500 regimen in a clinical practice setting.
These results are complementary to the primary clinical
trial findings, which showed significantly improved gly-
cemic control with low incidence and rates of severe
hypoglycemia with fewer daily injections [3]. These results
can be further complemented by appropriately designed,
prospective, real-world analyses accounting for other pa-
tient and economic factors that were not studied here.
Abbreviations
ANCOVA: analysis of covariance; BID: twice daily; EQ-5D-5L: quality of life
questionnaire; HbA1c: glycated hemoglobin; MMRM: mixed-effect model
repeated measures; TDD: total daily dose; TID: thrice daily; TRIM-D: Treatment
Related Impact Measure-Diabetes; U-500R: human regular U-500 insulin;
VAS: visual analog scale; VAS-ISP: Visual Analog Scale-Injection Site Pain
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